PKM2 is involved in neuropathic pain by regulating ERK and STAT3 activation in rat spinal cord

ConclusionOur findings demonstrate that inhibiting PKM2 expression effectively attenuates CCI-induced neuropathic pain and inflammatory responses in rats, possibly through regulating ERK and STAT3 signaling pathway.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research

Related Links:

We examined the expression of TRPV1 in peripheral tissue and DRG neurons of CPIP model rats and we studied whether CPIP model could induce peripheral sensitization of TRPV1 channel and enhance DRG neuron excitability. Then we examined the therapeutic effects of locally applied TRPV1 specific antagonist AMG9810 on pain responses of CPIP model rats. Lastly, we explored the effects of AMG9810 on DRG neuron hyperexcitability and spinal glial activation induced by CPIP. Our results demonstrate that TRPV1 plays an important role in mediating the behavioral hypersensitivity of CPIP model rats via promoting peripheral nociceptor a...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusion: These findings support the hypothesis that in FM a deteriorated function of cortical inhibition, indexed by a higher SICI parameter, a lower function of the DPMS, together with a higher level of BDNF indicate that FM has different pathological substrates from depression. They suggest that an up-regulation phenomenon of intracortical inhibitory networks associated with a disruption of the DPMS function occurs in FM. Introduction Major depressive disorder (MDD) and fibromyalgia (FM) present overlapped symptoms. Although the connection between these two disorders has not been elucidated yet, the disruption...
Source: Frontiers in Human Neuroscience - Category: Neuroscience Source Type: research
Tomoya Nakamachi1*, Ayano Tanigawa1, Norifumi Konno1, Seiji Shioda2 and Kouhei Matsuda1 1Laboratory of Regulatory Biology, Graduate School of Science and Engineering, University of Toyama, Toyama, Japan 2Innovative Drug Discovery, Global Research Center for Innovative Life Science, Hoshi University, Tokyo, Japan Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide with potent suppressive effects on feeding behavior in rodents, chicken, and goldfish. Teleost fish express two PACAPs (PACAP1, encoded by the adcyap1a gene, and PACAP2, encoded by the adcyap1b gene) and two PACAP receptors (PAC...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Conclusion and Perspectives Since their cloning 20 years ago, the physiological importance of TREK-1 channels has continued to grow (Figure 3). Today, TREK-1 channels have been shown to be important and their presence is essential in a number of physiopathological processes. Their involvement in these different processes demonstrate the necessity to design pharmacological modulators, activators or inhibitors, of these channels to correct any TREK-1-related dysfunctions. Despites a number of studies and many molecule screenings, only few putative new drugs were identified. The activators belonging to the ML and BL series ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
ConclusionCell transplantation appears to be a safe therapeutic strategy possessing substantial beneficial effects in the patients with SCI in clinic. Moreover, treating SCI with stem cell, the dosage of cells between 1 –5 × 107 and 10 –20 × 107, in intermediate or chronic phase, minimally invasive techniques, may bring more advantage to SCI patient.Graphical abstractThese slides can be retrieved under Electronic Supplementary Material.
Source: European Spine Journal - Category: Orthopaedics Source Type: research
CONCLUSIONS: Intranasal oxytocin attenuates measures of reactive and non-reactive pain in a model of mild TBI and may represent a novel treatment for chronic pain in TBI patients. PMID: 29266199 [PubMed - as supplied by publisher]
Source: Headache - Category: Neurology Authors: Tags: Headache Source Type: research
ConclusionsIntranasal oxytocin attenuates measures of reactive and non‐reactive pain in a model of mild TBI and may represent a novel treatment for chronic pain in TBI patients.
Source: Headache: The Journal of Head and Face Pain - Category: Neurology Authors: Tags: Research Submissions Source Type: research
Last week I discussed some of the areas in the brain, and basic principles, that are currently thought to influence our pain experience. This week I thought I’d introduce one of my favourite ways of considering pain mechanisms, mainly because it helps me think through the four main kinds of mechanisms, and can influence our treatment approach. At this stage I want to raise my hand to acknowledge the following: My gratitude to Dr John Alchin, longtime friend and colleague, who first pointed this paper out to me and has shared it with hundreds of people who go to see him at the local tertiary pain management centre. W...
Source: HealthSkills Weblog - Category: Anesthesiology Authors: Tags: Education Pain Pain conditions Research Science in practice biopsychosocial Chronic pain Health pain management Source Type: blogs
AbstractBackgroundHyperbaric oxygen (HBO) therapy is proven to attenuate neuropathic pain in rodents. The goal of the present study was to determine the potential involvement of the Kindlin-1/Wnt-10a signaling pathway during astrocyte activation and inflammation in a rodent model of neuropathic pain.MethodsRats were assigned into sham operation, chronic constriction injury (CCI), and CCI  + HBO treatment groups. Neuropathic pain developed in rats following CCI of the sciatic nerve. Rats in the CCI + HBO group received HBO treatment for five consecutive days beginning on postoperative day 1. The ...
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research
Soterix Medical said today it won Health Canada approval for and launched its PainX transcranial direct current stimulation technology designed for treating pain disorders in adults. The PainX tDCS system is a non-invasive, battery-powered device designed to deliver mild current to a specific section of the cerebral cortex to modulate reaction to painful experiences or control pain perception, Soterix said. The company touted the device as a “highly-promising therapy” that avoids systemic side effects associated with oral pain medications. “One in 5 Canadian adults suffer from chronic pain. We a...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Neuromodulation/Neurostimulation Pain Management Regulatory/Compliance Soterix Medical Source Type: news
More News: Back Pain | Brain | Chronic Pain | Genetics | Headache | Migraine | Neurology | Pain | Spinal Cord Injury | Study